Company profile
Allarity Therapeutics, Inc.
NASDAQ:ALLRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| 2X-121 | phase2 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04796324 | phase2 | terminated | 2021-03-01 | 2024-12-01 | Allarity Therapeutics | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. |
| NCT03562832 | phase2 | completed | 2018-06-20 | 2024-04-01 | Allarity Therapeutics | Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP |
| NCT03878849 | phase2 | recruiting | 2019-04-15 | 2027-03-01 | Allarity Therapeutics | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer |
| NCT03643107 | phase2 | completed | 2018-10-17 | 2021-10-01 | Allarity Therapeutics | Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) |
| NCT01861496 | phase1_2 | completed | 2013-04-01 | 2021-10-01 | Allarity Therapeutics | Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours |
FDA applications (0)
No records yet.